article thumbnail

Logical Fallacy in Patent Law: Analysing Abolkheir’s Challenge to the Soundness of Non-obviousness Test

SpicyIP

Dr. Abolkheir labels the inherent fallacy within patent law as “ inventio ad hominem ” fallacy. Questioning the logical foundations of patent laws, he argues that defining ‘inventive step’ in terms of ‘non-obviousness’ shifts the focus of inquiry to the inventor, rather than the invention itself.

article thumbnail

SCOTUS, Vaccine Mandates and Patent Law: God Help Us

IP Watchdog

The question is often discussed in private among patent attorneys who find themselves completely befuddled by the wanton disregard and open duplicitous handling of patent laws by the Nation’s High Court. The whim and fancy – and intellectual dishonesty – of the Supreme Court knows no bounds when it comes to patent law.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Judge Newman on Saving Patent Law

Patently-O

by Dennis Crouch Washington Post has published a long article titled, “ Colleagues want a 95-year-old judge to retire. The article ends with a noteworthy quote from Newman that rings true to her characteristic resilience and dedication: “ I want to spend my last five years correcting my colleagues’ mistakes.”

article thumbnail

Board of Appeal finds that human/pig chimeras are a risk to human dignity (T 1553/22)

The IPKat

The decision provides important guidance on how the morality exclusion under Article 53(a) EPC should be interpreted in the context of biotechnological inventions involving human-animal chimeras. Kat-pig Final Thoughts In T 1553/22 , the Board of Appeal provided an outline for assessing chimeric stem cell inventions under Article 53(a) EPC.

Invention 102
article thumbnail

Examining Upcoming Changes to the Implementing Regulations of the Chinese Patent Law

IP Watchdog

Recently, amendments to the Implementing Regulations of the Chinese Patent Law were issued and will take effect from January 20, 2024. The Regulations align with the revisions made to the Patent Law in 2020 and provide further guidance.

article thumbnail

Canadian Patent law 2022: A Year in Review

JD Supra Law

2022 was an active year in Canadian patent law. Claim fees were introduced for the first time; changes were made to regulations providing remedies for excessive pricing of patented medicines; and a range of court decisions addressed important issues. We considered over 60 patent decisions reported last year.

article thumbnail

The Fast and the Furious: Article 76 Proceedings in China Proceed with Speed

JD Supra Law

Article 76 of the Fourth Amendment1 to the Chinese Patent Law links regulatory approval of a generic drug and patent protection of the brand-name drug. It establishes a legal framework for resolving drug patent disputes before approval of the generic drug product similar to the Hatch-Waxman Act in the United States.